Cellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin Pharmace...
17 Juin 2021 - 12:58AM
Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of
innovative technology that enables the functional selection of stem
cells, announced today that it has filed a registration statement,
including a joint proxy statement/prospectus (“Proxy Statement”),
with the Securities and Exchange Commission (SEC) in connection
with its proposed strategic merger with privately-held Quoin
Pharmaceuticals. Quoin is a specialty pharmaceutical company
focused on rare and orphan diseases. Quoin’s leadership team is
made up of industry veterans, with extensive relevant executive
experience and proven records of recent success in the
pharmaceutical industry. The transaction is currently expected to
close in the 2021 third quarter.
The Company believes the progress of Quoin’s
clinical programs, and the secured investments of $25.5 million,
will benefit and maximize Cellect shareholders. In addition, the
Company believes that the payments to be distributed to Cellect’s
pre-closing shareholders under the Contingent Value Right (CVR)
could add a significant component to the overall value received by
the Cellect shareholders as a result of this transaction.
Stockholders are advised to read definitive
Proxy Statement, when the Company furnishes the Proxy Statement to
stockholders in connection with the solicitation of proxies for the
special meeting of stockholders. The definitive Proxy Statement
will contain important information. The definitive Proxy Statement
will be mailed to stockholders as of a record date to be
established for voting on the proposed merger.
About Cellect Biotechnology
Ltd.
Cellect Biotechnology (APOP) has developed a breakthrough
technology for the selection of stem cells from any given tissue
that aims to improve a variety of cell-based therapies.
The Company's products are expected to provide
researchers, clinicians and pharmaceutical companies with the tools
to rapidly isolate specific cells in quantity and quality, allowing
cell-based treatments and procedures in a wide variety of
applications in regenerative medicine. The Company's lead product
is currently in FDA approved clinical trial is aimed at bone marrow
transplantations in cancer treatment.
Forward Looking Statements This
press release contains forward-looking statements about the
Company's expectations, beliefs and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. In addition, historical results or
conclusions from scientific research and clinical studies do not
guarantee that future results would suggest similar conclusions or
that historical results referred to herein would be interpreted
similarly in light of additional research or otherwise. The
following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: the Company's history of losses and needs for
additional capital to fund its operations and its inability to
obtain additional capital on acceptable terms, or at all; the
Company's ability to continue as a going concern; or maintain its
current operations; uncertainties involving any strategic
transaction the Company may decide to enter into as the result of
its current efforts to explore new strategic alternatives;
uncertainties of cash flows and inability to meet working capital
needs; the Company's ability to obtain regulatory approvals; the
Company's ability to obtain favorable pre-clinical and clinical
trial results; the Company's technology may not be validated and
its methods may not be accepted by the scientific community;
difficulties enrolling patients in the Company's clinical trials;
the ability to timely source adequate supply of FasL; risks
resulting from unforeseen side effects; the Company's ability to
establish and maintain strategic partnerships and other corporate
collaborations; the scope of protection the Company is able to
establish and maintain for intellectual property rights and its
ability to operate its business without infringing the intellectual
property rights of others; competitive companies, technologies and
the Company's industry; unforeseen scientific difficulties may
develop with the Company's technology; and the Company's ability to
retain or attract key employees whose knowledge is essential to the
development of its products. Any forward-looking statement in this
press release speaks only as of the date of this press release. The
Company undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual
Report on Form 20-F for the fiscal year ended December 31, 2020
filed with the U.S. Securities and Exchange Commission, or SEC,
which is available on the SEC's website, www.sec.gov, and in the
Company's periodic filings with the SEC.
ContactCellect Biotechnology
Ltd.Eyal Leibovitz, Chief Financial
Officerwww.cellect.co+972-9-974-1444Or
EVC Group LLCMichael Polyviou(732)
933-2754mpolyviou@evcgroup.com
Cellect Biotechnology (NASDAQ:APOP)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Cellect Biotechnology (NASDAQ:APOP)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024